| Literature DB >> 28583150 |
Fabian Völker1, Paul Cooper2, Oliver Bader1, Angela Uy1, Ortrud Zimmermann1, Raimond Lugert1, Uwe Groß3,4.
Abstract
BACKGROUND: Although infectious diseases still account for a high burden of morbidity and mortality in sub-Saharan Africa, simultaneous investigations on multiple infections affecting maternal and child health are missing.Entities:
Keywords: Ghana; Group B streptococci; Hepatitis B; Infections; Malaria; Pregnancy
Mesh:
Substances:
Year: 2017 PMID: 28583150 PMCID: PMC5460405 DOI: 10.1186/s12884-017-1351-3
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
List of applied serological assays
| Object of assay | Test system | Producer |
|---|---|---|
| Toxo-IgM | VIDAS Toxo-IgM ELFA | bioMérieux, France |
| Toxo-IgG | VIDAS Toxo-IgG ELFA | bioMérieux, France |
| Toxo-IgG Avidity | VIDAS Toxo-IgG avidity ELFA | bioMérieux, France |
| HBsAg (HBV) | HBsAg(v2)/AXSYM | Abbott, Germany |
| HBsAg (HBV) | HBsAg EIA Test Kit | Ascon, USA (for comparison; rapid test with excellent performance used in Ghana) |
| HBeAg (HBV) | HBeAg(v2)/AXSYM | Abbott, Germany |
| Anti-HCV-IgG | HCV version 3.0 Anti-HCV | Abbott, Germany |
| Anti-HCMV-IgM/IgG | Cytomegalovirus IgM/IgG | Serion ELISA classic, Germany |
| Rubella IgM/IgG | Rubella virus (IgM/IgG) | Serion ELISA classic, Germany |
| HIV Ag/Ab | HIV Ag/Ab Combo | Abbott, Germany |
| Anti-PB19-IgM/IgG | Parvovirus B19 IgM/IgG | Mikrogen recomWell, Germany |
| Anti-VZV-IgA/IgG | Varicella-zoster virus (IgA/IgG) | Serion ELISA classic, Germany |
| Anti-HSV-IgM/IgG | Herpes simplex virus 1 + 2 IgM/IgG | Serion ELISA classic, Germany |
|
| Serodia TPPA | Fujirebio, Japan |
|
| FTA-ABS | Sekisui Diagnostics, Japan |
| Cardiolipin-Ig | VDRL | Omega Diagnostics, Germany |
Prevalence of pathogens, pathogen-specific antigens and antibodies in the study population
| Pathogen |
| Serological assays | Direct proof | ||
|---|---|---|---|---|---|
| IgM | IgG | IgA | |||
| Current pregnancy-relevant infections | |||||
|
| 174 | - | - | - | 16·7%e |
|
| 180 | - | - | - | + 6·1% |
|
| 180 | - | - | - | 10·6% |
|
| 174 | N/A | 1·1% | N/A | - |
|
| 173 | 0·6%* | 0·6%* | 0·6%* | - |
|
| 177 | - | - | - | 1·7% |
|
| 174 | 11·5% | 100% | N/A | 1·1%d |
| High susceptibility for potentially acquiring primary infection | |||||
| VZV | 169 | n.d. | 56·8% | 2.4% | - |
|
| 168 | 1·8%** | 73·2% | n.d. | - |
|
| 170 | 4·7% | 80·0% | N/A | - |
|
| 172 | 4·7% | 84·3% | N/A | - |
| Past pregnancy-relevant infections | |||||
| CMV | 172 | 0% | 100% | N/A | - |
|
| 180 | 0%+ | 2·8 / 5·0%++ | N/A | - |
| Absence of pregnancy-relevant infections | |||||
| N. gonorrhoeaec | 180 | - | - | - | 0 |
|
| 180 | - | - | - | 0 |
Direct pathogen proof was carried out by antigen testa, microscopy and countingb, cultivationc, or PCRd . eFive out of 23 tested HBsAg positive women (21.7%) were also HBeAg positive. -: not applicable. N/A: not available, n.d.: not done. *the assay used does not discriminate between antibody and antigen, **IgM-positive samples with high IgG avidity, +VDRL, ++FTA-ABS/TPPA